NASDAQ:CHFS Nuwellis - CHFS Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$4.52▼$5.5450-Day Range$3.53▼$6.0252-Week Range$4.86▼$37.50Volume305,376 shsAverage Volume467,323 shsMarket Capitalization$29.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Nuwellis (NASDAQ:CHFS) StockNuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.Read More Receive CHFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Email Address CHFS Stock News HeadlinesMarch 11, 2023 | forbes.comBest Prenatal Vitamins Of 2023, According To ExpertsFebruary 20, 2023 | forbes.comBest Multivitamins For Kids In 2023, According To ExpertsMarch 20, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.October 19, 2022 | globenewswire.comNuwellis Announces Appointment of Chief Financial Officer - GlobeNewswireOctober 18, 2022 | streetinsider.comForm 424B4 Nuwellis, Inc. - StreetInsider.comOctober 17, 2022 | uk.investing.comWhy Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday By Benzinga - Investing.com UKOctober 14, 2022 | uk.investing.comWhy Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session By Benzinga - Investing.com UKOctober 14, 2022 | benzinga.comWhy Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday’s Mid-Day Session - Agri - BenzingaMarch 20, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.October 14, 2022 | uk.investing.comWhy IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket By Benzinga - Investing.com UKOctober 14, 2022 | globenewswire.comNuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering - GlobeNewswireOctober 4, 2022 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 2.66% - msnNOWOctober 4, 2022 | streetinsider.comNuwellis (NUWE) Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA - StreetInsider.comOctober 3, 2022 | in.investing.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 2.66% - Investing.com IndiaOctober 3, 2022 | benzinga.comNuwellis shares are trading higher after the company announced results of the AVOID-HF clinical study ana - BenzingaOctober 3, 2022 | finance.yahoo.comNuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting - Yahoo FinanceOctober 3, 2022 | globenewswire.comNuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting - GlobeNewswireSeptember 27, 2022 | benzinga.comNuwellis Announces Activation Of New Sites For Its Pivotal REVERSE-HF Trial - Nuwellis (NASDAQ:NUWE) - BenzingaSeptember 27, 2022 | finance.yahoo.comNuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial - Yahoo FinanceSeptember 27, 2022 | globenewswire.comNuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial - GlobeNewswireAugust 31, 2022 | nasdaq.comHealth Care Sector Update for 08/31/2022: NUWE,BNR,SRNE,OSCR - NasdaqAugust 31, 2022 | benzinga.comNuwellis, Inc. - Common Stock (NUWE) – Nuwellis shares are trading higher after the company announced new - BenzingaAugust 31, 2022 | benzinga.comNuwellis, Inc. - Common Stock (NUWE) – Peering Into Nuwellis's Recent Short Interest - BenzingaAugust 31, 2022 | finance.yahoo.comNuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients - Yahoo FinanceAugust 31, 2022 | investorplace.comWhy Is Nuwellis (NUWE) Stock Up 110% Today?August 31, 2022 | globenewswire.comNuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients - GlobeNewswireAugust 25, 2022 | benzinga.comU.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology - BenzingaSee More Headlines Receive CHFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Email Address CHFS Company Calendar Last Earnings3/01/2021Today3/20/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical Equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHFS Previous SymbolNASDAQ:SSH CUSIPN/A CIK1506492 Webwww.chf-solutions.com Phone(952) 345-4200FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($279.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,110,000.00 Net Margins-254.26% Pretax MarginN/A Return on Equity-173.61% Return on Assets-131.01% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio5.97 Sales & Book Value Annual Sales$5.51 million Price / Sales5.27 Cash FlowN/A Price / Cash FlowN/A Book Value$12.79 per share Price / Book0.38Miscellaneous Outstanding Shares6,037,000Free FloatN/AMarket Cap$29.04 million OptionableNot Optionable Beta1.55 Key ExecutivesNestor JaramilloPresident, Chief Executive Officer, CFO & DirectorVitaliy EpshteynSenior Vice President-Operations & EngineeringDavid LernerChief Technology OfficerThomas P. LynchSecretary, Chief Legal & Compliance OfficerLaurent DuhouxVice President-International Business DevelopmentKey CompetitorsSoleno TherapeuticsNASDAQ:SLNOelectroCoreNASDAQ:ECORVivani MedicalNASDAQ:VANIENDRA Life SciencesNASDAQ:NDRABioSig TechnologiesNASDAQ:BSGMView All Competitors CHFS Stock - Frequently Asked Questions How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:CHFS) issued its quarterly earnings data on Monday, March, 1st. The company reported ($1.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.91) by $0.34. The business earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%. When did Nuwellis' stock split? Nuwellis's stock reverse split on Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nuwellis investors own include Biocept (BIOC), Immutep (IMMP), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Zosano Pharma (ZSAN), Avinger (AVGR), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO) and Onconova Therapeutics (ONTX). What is Nuwellis' stock symbol? Nuwellis trades on the NASDAQ under the ticker symbol "CHFS." What is Nuwellis' stock price today? One share of CHFS stock can currently be purchased for approximately $4.81. How much money does Nuwellis make? Nuwellis (NASDAQ:CHFS) has a market capitalization of $29.04 million and generates $5.51 million in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($279.28) on an earnings per share basis. How can I contact Nuwellis? Nuwellis' mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The official website for the company is www.chf-solutions.com. The company can be reached via phone at (952) 345-4200 or via email at ir@chf-solutions.com. This page (NASDAQ:CHFS) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.